

## References

### I-237

1. Pepaxto (melphalan flufenamide), for injection, for intravenous use [package insert]. Oncopeptides Inc., Waltham, MA. Revised 02/2021
2. Richardson, P. G., Oriol, A., Larocca, A., et.al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. *Journal of Clinical Oncology*, 2021; 39(7):757-767.
3. Byrgazov K, Anderson C, Salzer B, et al. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. *Therapeutic advances in medical oncology*. 2020;12:1758835920937891.
4. Bringhen, S., Voorhees, P. M., Plesner, T., et.al . Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: Long-term survival follow-up from the Phase II study O-12-*British journal of haematology*. 2021
5. Clinical Pharmacology™ 2021. Tampa FL: Gold Standard, Inc. Melphalan flufenamide.
6. National Comprehensive Cancer Network (NCCN). Melphalan flufenamide (Pepaxto). NCCN Drugs and Biologics Compendium®. 2021.